Roy Freeman, MD
Neurology · Boston, MANPI 1518905876
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $343,823 of the $390,330 with a category attached, or 88.1%. It is spread thinly across 22 manufacturers, the largest accounting for just 21.3%. Reporting peaked in 2021 at $170,382 and has fallen 89.0% since, to $18,795 in 2025. Among neurology clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 109 payments — averaging $3581.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Vertex$83K
- GW Pharma Limited$74K
- GW Research Limited$53K
- Eli Lilly$35K
- GSK$31K
- GRT US Holding, Inc.$24K
- plus $91K from 16 others
Across 164 payments — averaging $4686.86 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Akcea Therapeutics, Inc.$283K
- Biogen$155K
- H. Lundbeck A S$147K
- Regeneron$132K
- Takeda Pharmaceuticals U.S.A., Inc.$33K
- Biohaven Pharmaceuticals, Inc.$14K
- plus $4K from 1 others
What the payments were for
- Consulting fees$343,82388%
- Speaking & faculty fees$24,6886%
- Travel & lodging$19,9315%
- Food & beverage$1,8780%
- Education$100%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Vertex | 27 | $83,012 |
| GW Pharma Limited | 22 | $73,686 |
| GW Research Limited | 2 | $52,550 |
| Eli Lilly | 3 | $34,938 |
| GSK | 6 | $30,991 |
| GRT US Holding, Inc. | 6 | $24,454 |
| Lundbeck LLC | 4 | $15,200 |
| Orion Corporation | 5 | $12,334 |
| Pfizer | 1 | $11,050 |
| Collegium Pharmaceutical, Inc. | 2 | $8,125 |
| Greenwich Biosciences, Inc. | 1 | $7,270 |
| Akcea Therapeutics, Inc. | 11 | $6,595 |
| SK Life Science, Inc. | 1 | $6,000 |
| H. Lundbeck A S | 3 | $5,128 |
| PTC Therapeutics, Inc. | 7 | $5,010 |
| Astrazeneca UK Limited | 1 | $3,850 |
| Novartis | 1 | $3,341 |
| Novartis Pharma AG | 1 | $2,555 |
| Janssen Global Services, LLC | 1 | $2,480 |
| Biogen | 2 | $991 |
| AbbVie | 1 | $690 |
| Mylan Specialty L.p. | 1 | $80 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Qutenza$24,330
- TEGSEDI$6,313
- Cenobamate$6,000
- AIMOVIG$2,555
How this compares
$390,330 in reported general payments places this provider in the 95th percentile of 761 neurology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Droxidopa | 11 | $4,801 |
Paid to pharmacies, not to this prescriber.
Other neurology in Boston
- Christopher WrightBoston$2.5M
- Thomas ScammellBoston$617K
- Alfred SandrockBoston$490K
- Pushpa NarayanaswamiBoston$420K
- Michael LevyBoston$387K
- Leeann BurtonBoston$325K
- Ilena GeorgeBoston$316K
- Andrew BudsonBoston$304K
- Denis BalabanBoston$297K
- Sheena ChewBoston$262K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.